292 related articles for article (PubMed ID: 29265099)
1. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
Boyko AN; Alifirova VM
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
[TBL] [Abstract][Full Text] [Related]
2. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S;
Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
McKeage K
CNS Drugs; 2015 May; 29(5):425-32. PubMed ID: 25906331
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
[TBL] [Abstract][Full Text] [Related]
5. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis.
Ziemssen T; Ashtamker N; Rubinchick S; Knappertz V; Comi G
Expert Opin Drug Saf; 2017 Feb; 16(2):247-255. PubMed ID: 27989217
[TBL] [Abstract][Full Text] [Related]
7. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
[TBL] [Abstract][Full Text] [Related]
9. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.
Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
Mult Scler Relat Disord; 2019 Aug; 33():13-21. PubMed ID: 31132664
[TBL] [Abstract][Full Text] [Related]
10. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
[TBL] [Abstract][Full Text] [Related]
11. Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.
Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
Mult Scler Relat Disord; 2020 May; 40():101957. PubMed ID: 32028117
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis.
Schipper HM; Arnold D; GrandʼMaison F; Melmed C; Moore F; Levental M; Su H; Constantin M; Stril JL; Godin J
Clin Neuropharmacol; 2015; 38(4):127-31. PubMed ID: 26166235
[TBL] [Abstract][Full Text] [Related]
13. Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
Lebrun-Frenay C; Moulignier A; Pierrot-Deseilligny C; Benrabah R; Moreau T; Lubetzki C; Monchecourt F;
J Neurol; 2019 Apr; 266(4):888-901. PubMed ID: 30730008
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Zagmutt FJ; Carroll CA
Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.
Boster AL; Ford CC; Neudorfer O; Gilgun-Sherki Y
Expert Rev Neurother; 2015 Jun; 15(6):575-86. PubMed ID: 25924547
[TBL] [Abstract][Full Text] [Related]
17. [The resolution of the expert body for the section on demyelinating diseases of the Russian Society of Neurologists and Russian Executive Committee of multiple sclerosis researchers (Kazan, 19 november 2015) on the 'Current principles and optimization of treatment of patients with relapsing-remitting multiple sclerosis with glatiramer acetate'].
Redaktsiia
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):78-79. PubMed ID: 28635770
[No Abstract] [Full Text] [Related]
18. Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.
Schreiber H; Hipp J; Roßnagel F; Moritz C
Neurodegener Dis Manag; 2023 Oct; 13(5):281-288. PubMed ID: 37909320
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer Acetate: from Bench to Bed and Back.
Arnon R; Aharoni R
Isr Med Assoc J; 2019 Mar; 21(3):151-157. PubMed ID: 30905097
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
